Clinical trials: Stem Cell Transplants
Acute Myelocytic Leukemia, Myelodysplastic Syndromes
Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Allo - hematopoietic stem cell transplantation is currently the only way to cure myelodysplastic syndrome /acute leukemia . The existing experimental results showed that decitabine and 5-azacytidine up-regulated the expression of…
- Trial name
- NCT01809392
- Testing
- decitabine
- Where
- China
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Soochow University
Congenital Hemolytic Anemia, Sickle Cell Disease
Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
People with severe congenital anemias, such as sickle cell anemia and beta-thalassemia, have been cured with bone marrow transplantation (BMT).
- Trial name
- NCT00061568
- Testing
- Peripheral blood hematopoietic progenitor cell (PBPC) transplant, Alemtuzumab, Peripheral blood hematopoietic progenitor cell Apheresis
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphoma
S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00005090
- Testing
- bleomycin sulfate, carmustine, cyclophosphamide
- Where
- 47 sites in United States
- Volunteers
- 11 people
- Sponsor
- SWOG Cancer Research Network
Skin Carcinoma
Technology-Enabled Activation of Skin Cancer Screening for Stem Cell Transplant Survivors and Their Primary Care Providers, TEACH Study
This trial studies the impact of a 12-month invention focused on early detection of skin cancer and timely follow up in patients who underwent stem cell transplant and their primary care providers.
- Trial name
- NCT04358276
- Testing
- Computer-Assisted Intervention, Dermatoscope, Educational Intervention
- Where
- United States
- Volunteers
- 840 people
- Sponsor
- City of Hope Medical Center
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission
This phase II trial studies how well iodine I 131 monoclonal antibody BC8, busulfan, and cyclophosphamide followed by donor stem cell transplant works in treating patients with acute myeloid leukemia that has decreased or…
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT00005940
- Testing
- iodine I 131 monoclonal antibody BC8, busulfan, cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Fred Hutchinson Cancer Center
Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
This phase II trial is studying how well giving iodine I 131 tositumomab together with etoposide and cyclophosphamide followed by autologous stem cell transplant works in treating patients with relapsed or refractory…
- Conditions
- Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
- Trial name
- NCT00073918
- Testing
- cyclophosphamide, etoposide, iodine I 131 tositumomab
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma, Leukemia
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
Background: Patients with cancers of the blood and immune system often benefit from transplants of stem cells from a genetically well-matched sibling.
- Conditions
- Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma
- Trial name
- NCT00074490
- Testing
- Rituximab, Fludarabine, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 442 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Graft-Versus-Host Disease
Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT
Ocular Graft Versus Host Disease (OGVHD) is a serious potential complication of allogeneic bone marrow transplants. The usual treatment is topical cyclosporine but when the treatment is initiated the damage to the lacrimal glands…
- Trial name
- HSCT (NCT02144025)
- Testing
- Cyclosporine
- Where
- Mexico
- Volunteers
- 21 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Multiple Myeloma
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
The purpose of the study is to determine outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post Autologous Stem Cell Transplant (ASCT).
- Trial name
- NCT05271630
- Testing
- Autologous Stem Cell Transplant, Immunomodulatory Agent, Proteasome Inhibitor
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
This phase I/II trial studies the side effects and best dose of donor natural killer cells when given together with donor stem cell transplant and to see how well they work in treating patients with myeloid malignancies that are…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT01823198
- Testing
- Aldesleukin, Allogeneic CD56-positive CD3-negative Natural Killer Cells, Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells.
- Trial name
- NCT00016887
- Testing
- filgrastim, recombinant interferon alfa, carmustine
- Where
- 2 sites in Belgium, Italy
- Sponsor
- German Low Grade Lymphoma Study Group
Multiple Myeloma
T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant
Patients will have immune cells collected and then expanded outside of the body. Patients will undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation.
- Trial name
- NCT00048464
- Testing
- Infusion of Activated & Expanded Autologous T Cells
- Where
- 6 sites in United States
- Volunteers
- 35 people
- Sponsor
- Xcyte Therapies
Multiple Myeloma
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd)…
- Trial name
- CARTITUDE-6 (NCT05257083)
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- 106 sites in United States, Australia and 14 more
- Volunteers
- 759 people
- Sponsor
- Stichting European Myeloma Network
Graft vs Host Disease
Evaluation of the Role of Mesenchymal Stem Cells in the Treatment of Graft Versus Host Disease
Mesenchymal stem cells (MSC) have been shown to have immunosuppressive properties. Following a bone marrow/peripheral blood stem cell transplant, a proportion of patients develop a condition called 'graft versus host disease'…
- Trial name
- NCT00314483
- Testing
- Mesenchymal Stem Cell Infusion
- Where
- India
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Christian Medical College, Vellore, India
B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
This phase II trial studies giving rituximab before and after a donor peripheral blood stem cell transplant in patients with B-cell lymphoma that does not respond to treatment (refractory) or has come back after a period of…
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Childhood Burkitt Lymphoma
- Trial name
- NCT00867529
- Testing
- rituximab, peripheral blood stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma, Plasma Cell Leukemia
Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants
The primary objectives of this study are to: To determine the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen.
- Trial name
- NCT00307086
- Testing
- Bortezomib, Melphalan, PBSCT
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Epidermolysis Bullosa
Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (AlloSCT) from family-related donors and unrelated cord blood (UCB) donors will be safe and well tolerated in selected patients with RDEB.
- Trial name
- RDEB (NCT00881556)
- Testing
- Palifermin, Fludarabine, Busulfan
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Columbia University
Hematologic Malignancy, Stem Cell Transplant
Critical Care Outcomes of Hematologic Oncology Patients
Hematologic malignancy patients are admitted to ICU in increasing numbers. Successful ICU intervention has led to an increasing number of ICU survivors; however, there is a lack of information available about these patients' long…
- Trial name
- COHO (NCT03449953)
- Where
- 13 sites in Canada
- Volunteers
- 415 people
- Sponsor
- Mount Sinai Hospital, Canada
Lymphoma
Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00012051
- Testing
- filgrastim, rituximab, carmustine
- Where
- 17 sites in Belgium, Netherlands
- Volunteers
- 340 people
- Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
Lymphoma
Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
RATIONALE: Giving chemotherapy and radiation therapy to the entire body before an autologous peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00559104
- Testing
- carmustine, cyclophosphamide, etoposide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.